‘Brave launches a privacy-focused competitor to Zoom’ -Article From Protocol

https://www.protocol.com/bulletins/brave-talk-video-zoom

byBenzinga Newsdesk

September 22, 2021

1 minute read

https://www.protocol.com/bulletins/brave-talk-video-zoom

News

‘The representatives of Bharat Biotech are slated to meet WHO experts in a virtual meet at 4:45 pm. During the hour-long meeting, the vaccine manufacturer will present the clinical trial data of #Covaxin through all the three phases’ – Mirror Now

By Benzinga Newsdesk

Today, 5:39 PM

https://twitter.com/MirrorNow/status/1445342808647168000

OCGN

UCB Announced it Will Acquire Zogenix for $26/Share in Cash

By Charles Gross

Today, 5:39 PM

UCB (Euronext: UCB) and Zogenix (NASDAQ: ZGNX) announced today that the companies have entered into a definitive agreement under which UCB would acquire Zogenix, Inc., a global biopharmaceutical company commercializing and developing therapies for rare diseases.

ZGNX

8 Charts That Tell The Stock Market Story Of 2021

By Wayne Duggan

Today, 5:39 PM

Investors experienced another great year for stocks in 2021, with the SPDR S&P 500 ETF Trust (NYSE: SPY) on track to finish the year with a roughly 30% total return.

SPY

TC Biopharm Announces Priced ~4.11M Share/~8.23M Warrant IPO @$4.25

By Charles Gross

Today, 5:39 PM

TC Biopharm (Holdings) PLC ("TC Biopharm" or the "Company") (NASDAQ: TCBP) (NASDAQ: TCBPW), a clinical stage biotechnology company developing platform allogeneic gamma-delta T cell therapies for cancer and viral indications, today announced the pricing of

TCBP

‘Brave launches a privacy-focused competitor to Zoom’ -Article From Protocol

Related Posts

‘The representatives of Bharat Biotech are slated to meet WHO experts in a virtual meet at 4:45 pm. During the hour-long meeting, the vaccine manufacturer will present the clinical trial data of #Covaxin through all the three phases’ – Mirror Now

UCB Announced it Will Acquire Zogenix for $26/Share in Cash

8 Charts That Tell The Stock Market Story Of 2021

TC Biopharm Announces Priced ~4.11M Share/~8.23M Warrant IPO @$4.25